Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 1;64(6):787-795.
doi: 10.20945/2359-3997000000295. Epub 2020 Oct 9.

The polymorphic inheritance of DIO2 rs225014 may predict body weight variation after Graves' disease treatment

Ana Paula Comarella  1 , Danilo Vilagellin  2 , Natassia Elena Bufalo  3 , Jessica Ferreira Euflauzino  2 , Elisangela de Souza Teixeira  3 , Ana Beatriz Pinotti Pedro Miklos  4 , Roberto Bernardo Dos Santos  2 , João H Romaldini  2 , Laura S Ward  3
Affiliations

The polymorphic inheritance of DIO2 rs225014 may predict body weight variation after Graves' disease treatment

Ana Paula Comarella et al. Arch Endocrinol Metab. .

Abstract

Objective: We aimed to investigate the role of DIO2 polymorphisms rs225014 and rs12885300 in Graves' disease patients, mainly for controlling body weight following treatment.

Methods: We genotyped 280 GD patients by the time of diagnosis and 297 healthy control individuals using a TaqMan SNP Genotyping technique. We followed up 141 patients for 18.94 ± 6.59 months after treatment.

Results: There was no relationship between the investigated polymorphisms with susceptibility to GD and gain or loss of weight after GD treatment. However, the polymorphic inheritance (CC+CT genotype) of DIO2 rs225014 was associated with a lower body weight variation after GD treatment (4.26 ± 6.25 kg) when compared to wild type TT genotype (6.34 ± 7.26 kg; p = 0.0456 adjusted for the follow-up time). This data was confirmed by a multivariate analysis (p = 0.0138) along with a longer follow-up period (p = 0.0228), older age (p = 0.0306), treatment with radioiodine (p-value = 0.0080) and polymorphic inheritance of DIO2 rs12885300 (p = 0.0306).

Conclusion: We suggest that DIO2 rs225014 genotyping may have an auxiliary role in predicting the post-treatment weight behavior of GD patients.

Keywords: DIO2 gene; Graves’ Disease; polymorphisms.

PubMed Disclaimer

Conflict of interest statement

Disclosure: no potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1. ( A ) One hundred forty-one Graves’ Disease patients were followed for body weight. Anti-thyroid drug (ATD) group was composed by 43 patients treated only with ATD plus 55 patients initially treated with ATD. Radioiodine therapy (RAI) group was composed by 43 patients assigned to RAI (without previous ATD therapy) plus 55 patients who did not comply (relapse) with ATD administration and therefore were treated with RAI. The group ATD/RAI comprises the 55 initially treated with ATD patients and were further assigned to radioiodine therapy. ( B ) Hypothesis for DIO2 rs225014 and body weight variation in Graves’ Disease. *T3 from T4 intracellular deiodination.
Figure 2
Figure 2. Percentage of Graves’ disease patients classified as overt hyperthyroidism, subclinical hyperthyroidism, euthyroidism, subclinical hypothyroidism and overt hypothyroidism during follow-up.
Figure 3
Figure 3. Body weight variation for DIO2 rs225014 (weight in kg and percentage of BMI) in groups of GD patients (ANOVA, p adjusted for follow up time). All comparison TT versus CT+CC.
See this image and copyright information in PMC

References

    1. Smith TJ, Hegedüs L. Graves’ Disease. N Engl J Med. 2016;375(16):1552-65. - PubMed
    1. Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008;358(24):2594-605. - PubMed
    1. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724-34. - PubMed
    1. Bianco AC, Maia AL, da Silva WS, Christoffolete MA. Adaptive activation of thyroid hormone and energy expenditure. Biosci Rep. 2005;25(3-4):191-208. - PubMed
    1. Dale J, Daykin J, Holder R, Sheppard MC, Franklyn JA. Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf) [Internet]. 2001;55(2):233-9. Available from: 10.1046/j.1365-2265.2001.01329.x - DOI - PubMed

LinkOut - more resources